Price T Rowe Associates Inc Immuneering Corp Put Options Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding IMRX
# of Institutions
44Shares Held
4.59MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$1.86 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$938,7200.0% of portfolio
-
Morgan Stanley New York, NY454KShares$799,2160.0% of portfolio
-
Southport Management, L.L.C. Wilson, WY215KShares$378,4001.71% of portfolio
-
Geode Capital Management, LLC Boston, MA208KShares$366,7610.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $46.5M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...